Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QH103E in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06838832Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of QH103E in B-cell non-Hodgkin lymphoma, sponsored by Chinese PLA General Hospital. Started Jul 2025; status: recruiting.
02
Drugs
QH103E
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06838832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838832.